Sparks, NV – March 11, 2023: Ludwig Enterprises, Inc. (The Genomics Language Company™) and its subsidiary Precision Genomics has attracted significant clinical interest in its patent pending
Recent Posts
- June 21, 2023 Amendment to Form S-1 – Registration Statement Under The Securities Act Of 1933 – Ludwig Enterprises, Inc. – 47,000,000 Shares of Common Stock
- Ludwig Enterprises Announces Stock Listing on the Canadian Stock Exchange
- Ludwig Enterprises mRNA Program Generating Broad Clinical Interest
- Ludwig Enterprises, Inc. Chief Medical Officer Lectures UCF Students on mRNAand Chronic Inflammation
- New Scientific Evidence Suggests How Chronic Illnesses May Be Prevented